ER, PgR, Ki67, p27Kip1, and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab by Sasagu Kurozumi et al.
RESEARCH ARTICLE Open Access
ER, PgR, Ki67, p27Kip1, and histological
grade as predictors of pathological
complete response in patients with HER2-
positive breast cancer receiving neoadjuvant




Sasagu Kurozumi1, Kenichi Inoue2, Hiroyuki Takei1, Hiroshi Matsumoto1, Masafumi Kurosumi3*, Jun Horiguchi4,
Izumi Takeyoshi4 and Tetsunari Oyama5
Abstract
Background: Neoadjuvant chemotherapy (NAC) with taxanes followed by fluorouracil, epirubicin, and cyclophosphamide
(FEC), and concurrent trastuzumab is a potent regimen for HER2 over-expressing breast cancer. A high pathological
complete response (pCR) rate has been achieved using this regimen; however, the predictive factors and
prognostic effects of pCR currently remain unclear. In the present study, we determined whether pCR was related
to histological grade (HG) and several biological factors including p27Kip1. We also assessed the prognosis of the
pCR and non-pCR groups, and expected differences between those positive and negative for lymph node
metastasis after chemotherapy.
Methods: A total of 129 Japanese women with HER2-positive invasive breast cancer received either paclitaxel or
docetaxel followed by FEC, with the concomitant administration of trastuzumab. The statuses of HG, ER, PgR,
Ki67, and p27Kip1 were evaluated to determine their relationship with pCR. Relapse-free survival (RFS) and overall
survival (OS) were also analyzed for their relationship with pCR and pathological nodal involvement.
Results: pCR was obtained in 84 out of 129 patients and the pCR rate was 65.1 %. The pCR rates related to 5
factors were as follows: HG (grade 3, 70.0 % vs. grades 1–2, 36.8 %), ER (negative, 78.6 % vs. positive, 40.0 %), PgR
(negative, 75.3 % vs. positive, 38.9 %), Ki67 (high, 72.0 % vs. low, 47.2 %), and p27Kip1 (low, 71.0 % vs. high, 50.0 %).
RFS was significantly better in the pCR group than in the non-pCR group (p = 0.018). Patients with remaining
nodal disease in the pCR group had worse OS (p = 0.0002).
Conclusions: High-HG, low-ER, low-PgR, high-Ki67, and low-p27Kip1 were identified as predictive factors of pCR in
NAC with trastuzumab, while pCR and negative nodes were predictive of better survivals.
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Background
Many neoadjuvant chemotherapy (NAC) regimens for
breast cancer that use various cytotoxic agents are cur-
rently being performed in clinical studies as well as routine
practice, and NAC is considered a useful therapeutic op-
tion for advanced as well as early stage breast cancer pa-
tients. NAC improves surgical outcomes in advanced cases
for which mastectomy is technically impossible and in
early cases of operable breast cancer desiring breast con-
servative surgery. The therapeutic effects of NAC have
mainly been evaluated on the basis of the pathological find-
ings and results of most clinical studies including NSABP
protocol B-18 [1] and B-27 [2]. These studies confirmed
the prognostic significance of pathological complete re-
sponse (pCR). On the basis of these findings, pCR has
been positioned as a primary endpoint of NAC in many
clinical studies and clinical trials of new chemotherapeutic
agents.
Approximately 20 to 30 % of breast cancers over ex-
press human epidermal growth factor receptor 2 (HER2)
[3], and effective HER2-targeting agents such as trastu-
zumab have recently been added to NAC regimens [4–6].
However, the pCR rate of NAC using taxanes and trastu-
zumab has remained between 20 and 40 % [4, 7]. An
anthracycline has also been added to NAC regimens
with trastuzumab in an attempt to obtain a higher pCR
rate. Buzdar et al. [8] conducted a NAC regimen with
tri-weekly paclitaxel followed by fluorouracil, epirubicin,
and cyclophosphamide (FEC) concurrently with trastuzu-
mab on HER2-positive patients and achieved a pCR rate
of 66.7 % without serious adverse events. However, the
predictive factors of pCR in patients with HER2-positive
breast cancer receiving trastuzumab supplemented NAC
regimens have not been clarified.
In the present study, we analyzed several factors, such
as the histological grade (HG), ER status, PgR status, Ki67
(proliferation marker) labeling index (LI), and expression
of p27Kip1 (an anti-proliferation marker) in order to
identify more effective predictive markers for pCR after
NAC with trastuzumab. We also assessed differences in
survival between the pCR and non-pCR groups, and be-
tween patients who tested positive and negative for
lymph node metastasis.
Methods
Patient backgrounds and eligibility
Our study included 129 female patients with HER2-posi-
tive invasive breast cancer. They received NAC consisting
of 12 cycles of paclitaxel (80 mg/m2) every week or 4 cycles
of docetaxel (75 mg/m2) every 3 weeks followed by 4 cycles
of FEC-75 (5-fluorouracil, 500 mg/m2, epirubicin, 75 mg/
m2; and cyclophosphamide, 500 mg/m2) every 3 weeks.
All patients also received 4 mg/kg trastuzumab on day 1
of the treatment and 2 mg/kg trastuzumab every week
thereafter for a total of 24 cycles. NAC with trastuzumab
for these patients was performed to evaluate the impact of
pathological therapeutic effects evoked by additional ad-
ministration of trastuzumab, and the main aims of this
therapy for each patient were reduction of tumor size for
prior to breast-conserving surgery, and evaluation of drug
effect through pathological assessment of tumor response
and good prognosis in cases achieving pCR.
The main eligibility criteria were: age ≥20 years, an
Eastern Cooperative Oncology Group performance status
of 0–1, adequate oral intake, preserved major organ func-
tions, and the ability to provide informed consent. Patients
were excluded if they had a previous history of therapy for
breast cancer, inflammatory breast cancer, a history of se-
vere anaphylaxis or allergies to any drug, significant active
illness that may preclude the protocol treatment, a history
of uncompensated congestive heart failure, or severe men-
tal disease. Pregnant or lactating females were also ex-
cluded. This protocol is now accepted as standard care.
Approximately 97 % of patients completed this regimen of
treatment. However, some patients receiving the same
regimen of treatment were excluded from this study be-
cause their paraffin-embedded pre-treatment biopsy speci-
mens could not be obtained. In approximately 40 % of
patients, sentinel lymph node biopsy was performed using
a combination method with an isotope (99mTc-sulfur col-
loid) and blue dye.
We extracted information from the institutional clin-
ical and pathological database on all consecutive breast
cancer patients who underwent surgery between 2005
and 2011 at the Division of Breast Surgery in the Saitama
Cancer Center. All patients received an adjuvant trastuzu-
mab treatment for six months, and adjuvant endocrine
therapy using tamoxifen or an aromatase inhibitor was
performed on ER-positive patients. This study was con-
ducted in accordance with the Declaration of Helsinki,
and the protocol of NAC used in this study and associated
translational researches were approved by the Institutional
Review Board of the Saitama Cancer Center. All patients
enrolled in this study agreed to be treated with this NAC
regimen and provided written informed consent.
Evaluation of histological effects
Pathological effects after NAC were evaluated by 2 pa-
thologists according to the criteria proposed by the
Japanese Breast Cancer Society (JBCS). In these criteria,
pathological effects were categorized into 6°, such as grade
0, 1a, 1b, 2a, 2b, and 3, on the basis of morphological
changes and the extent or absence of invasive cancer.
Grade 1a was defined as “mild changes in cancer cells re-
gardless of the extent, and/or marked changes in <1/3 of
the tumor”. Grade 1b was defined as “marked changes in
1/3 to <2/3 of the tumor”. Grade 2a was defined as
“marked changes in ≥2/3 of the tumor, but apparent
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remaining cancer cells”. Grade 2b was defined as “marked
changes approaching a complete response with only a few
remaining cancer cells”. The JBCS defines “grade 3” as “no
invasive cancer in the breast”, which is equal to “pCR”
proposed in the NSABP B-18 study. The presence of
non-invasive cancers (DCIS) in the breast and nodal in-
volvement in such cases was clearly stated. This response
was designated as ypT0/is ypN0/1-3 according to the
TNM staging criteria of the AJCC (American Joint
Committee on Cancer Staging System).
Examination of biological markers in relation to pCR rates
The expression of ER, PgR, and HER2 proteins was exam-
ined by immunohistochemistry and HER2 gene amplifica-
tion was evaluated by fluorescence in situ hybridization
(FISH) using specimens obtained by needle biopsy as a
routine practice before NAC. On the other hand, the ex-
pression of Ki67 and p27Kip1 was retrospectively examined
by immunohistochemistry using needle biopsy specimens
as part of this study. Primary antibody sources were as fol-
lows: ER (1D5, DAKO, Denmark), PgR (PgR636, DAKO,
Denmark), HER2 (HercepTest, DAKO, Denmark), Ki67
(MIB-1, DAKO, Denmark), and p27Kip1 (Santa Cruz
Biotechnology, USA). Positive ER and PgR statuses
were defined by the presence of 1 % or more positive
nuclei. A high Ki-67 LI and strong expression of p27Kip1
were defined by the presence of 30 % and 75 % or more
positive nuclei, respectively (Fig. 1a). Cancer cells that
positively expressed p27Kip1 in the cytoplasm were catego-
rized as “negative” (Fig. 1b). The ER status (positive vs.
negative), PgR status (positive vs. negative), Ki67 LI (high
vs. low), and p27Kip1 expression (high vs. low) at baseline
were analyzed for their relationships with pCR.
Clinical outcome analysis
Clinical and tumor characteristics at baseline such as
age, menopausal status, clinical tumor size, clinical nodal
status, and HG (grades 1–2 vs. grade 3) were analyzed
for their relationship with pCR and with the presence of
pathological axillary lymph node metastasis. Recurrence-
free survival (RFS) and overall survival (OS) were
compared according to the achievement of pCR and
pathological nodal involvement.
Statistical analysis
Statistical analyses were conducted using Stat Mate 4 for
Windows (ATMS, Tokyo, Japan). The Chi-squared test
and Fisher’s exact test were used to analyze relationships
between clinicopathological characteristics and pCR. In
addition, a multivariate analysis of logistic regression was
used to determine which factors were independently asso-
ciated with pCR.
The Kaplan-Meier method and log-rank test were used
to estimate RFS and OS rates. RFS was defined as the
length of time from the period of surgery to any recurrence
(including ipsilateral breast recurrence). OS was deter-
mined as the time from the day of surgery until the time of
death (from any cause). The log-rank test was used to com-
pare survival rates between patients with pCR and those
with non-pCR. Survival rates were analyzed for their rela-
tionship with pathological nodal involvement in the pCR
group.
Results
Patient and tumor characteristics
The median age of the 129 patients enrolled in this
study was 53 years (age range, 27–73 years); 109 patients
(84.5 %) were older than 41 years and 78 patients
(60.5 %) were post-menopausal. Tumor sizes (AJCC) were
as follows: T1, 6 patients (4.7 %); T2, 81 patients (62.8 %);
T3, 26 patients (20.2 %); and T4, 16 patients (12.4 %). The
clinical lymph node status was as follows: N0, 41 patients
(31.8 %); N1, 59 patients (45.7 %); N2, 17 patients
(13.2 %); and N3, 12 patients (9.3 %). Breast cancer stages
were as follows: stage I, 2 patients (1.6 %); stage IIA, 37
patients (28.7 %); stage IIB, 38 patients (29.5 %); stage
IIIA, 29 patients (22.5 %); stage IIIB, 11 patients (8.5 %);
and stage IIIC, 12 patients (9.3 %). In 38.8 % of all cases,
Fig. 1 Immunohistochemical findings of p27Kip1. a Nuclei of cancer cells showing highly positive immunoreactions for p27
Kip1. b The cytoplasm
of cancer cells was weakly positive, whereas the nuclei were negative for p27Kip1
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lymph node dissection was avoided, because of negative
for metastasis in sentinel lymph nodes (Additional file 1);
the median number of nodes removed by axillary lymph
node dissection was 11 (range, 2–23) , and he median
number of nodes sampled only by sentinel lymph node bi-
opsy was 2 (range, 1–5).
Tumor response
Eighty-four (65.1 %) out of the 129 patients achieved
pCR (grade 3, JBCS criteria). Of these, 5 patients (3.9 %)
had lymph node metastasis (ypN1-3) and 31 (24.0 %)
had DCIS. The histological tumor responses of the 45
patients who did not achieve pCR (non-pCR) were as
follows: grade 2b (near-pCR), 11 patients (8.5 %); grade
2a, 17 patients (13.2 %); grade 1b, 12 patients (9.3 %);
and grade 1a, 5 patients (3.9 %). A prominent tumor re-
sponse (pCR and near-pCR) was detected in 73.6 % of
patients.
Patient and tumor characteristics and biological markers
associated with pCR
pCR rates were not associated with clinical T (p = 0.62),
clinical N (p = 0.96), or clinical stages (p = 0.97); however,
pCR rates correlated with the menopausal status (p =
0.019) (Table 1). pCR rates were also significantly higher
in patients with HG 3 (p = 0.005), ER-negative (p < 0.001),
and PgR-negative (p < 0.001) tumors than in those with
HG 1–2, ER-positive, and PgR-positive tumors, respect-
ively (Table 1). pCR rates were also significantly higher in
patients whose tumors had a high Ki67 LI (p = 0.008) or
weakly expressed p27Kip1 (p = 0.025) (Table 1). The multi-
variate analysis indicated that none of the factors were
significant (Additional file 2). Therefore, the relationship
between pCR rates and the 5 biological markers (HG, ER,
PgR, Ki67, and p27Kip1) combined was evaluated. One
point each was assigned for high HG, ER negative, PgR
negative, high Ki-67 LI, and low p27Kip1 expression. pCR
rates among patients with 5, 4, 3, 2, 1, and 0 points were
84.3 %, 74.1 %, 47.8 %, 47.1 %, 28.6 %, and none, respect-
ively. This pCR-predicting score significantly predicted
pCR (p = 0.0001) (Table 2 and Additional file 3).
Survival
The median RFS was 53 months (range, 3–108 months)
and median follow-up duration was 59 months (range,
13–108 months). RFS was significantly better in the 84
patients with pCR after NAC with trastuzumab than in
the 45 patients with non-pCR [hazard ratio (HR) = 0.40,
95 % CI = 0.15 to 0.79, p = 0.012] (Fig. 2). Of the 84 pa-
tients with pCR, OS was significantly worse in those
with pathologically involved nodes (ypT0/is ypN1-3)
(5 patients) than in those without pathologically in-
volved nodes (ypT0/is ypN0) (79 patients) (HR = 0.075, 95
% CI = 0.019 to 0.29, p = 0.0002) (Fig. 3). Among patients
with ER-positive tumors, pCR was significantly predictive
of better RFS if the tumors had a high Ki67 LI (p = 0.004);
however, pCR was not predictive of RFS rates if tumors
Table 1 Patient and tumor characteristics at baseline and their
relationship with pCR
pCR non-pCR pCR rate (%) p-value
Menopausal status
Premenopausal 27 24 52.9
Postmenopausal 57 21 73.1 0.019*
Clinical tumor size
T1 4 2 66.7
T2 56 25 9.1
T3 15 11 57.7
T4 9 7 56.2 0.62
Clinical nodal status
N0 27 14 65.9
N1 39 20 66.1
N2 11 6 64.7
N3 7 5 58.3 0.96
Clinical stage
I 1 1 50.0
IIA 26 11 70.3
IIB 24 14 63.2
IIIA 19 10 65.5
IIIB 7 4 63.6
IIIC 7 5 58.3 0.97
Type of Taxanes
Paclitaxel 78 39 66.7
Docetaxe 6 6 50.0 0.40
HG
High (3) 77 33 70.0
Low (1–2) 7 12 41.2 0.005*
ER
Negative (<1 %) 66 18 78.6
Positive (≥1 %) 18 27 40.0 <0.001*
PgR
Negative (<1 %) 70 23 75.3
Positive (≥1 %) 14 22 38.9 <0.001*
Ki67
High (≥30 %) 67 26 72.0
Low (<30 %) 17 19 47.2 0.008*
p27Kip1
Low (<75 %) 66 27 71.0
High (≥75 %) 18 18 50.0 0.025*
pCR, pathological complete response; HG, histological grade; ER, estrogen
receptor; PgR, progesterone receptor
*p < 0.05 was considered significant; all significant values are shown in bold
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showed a low Ki67 LI. pCR was significantly predictive of
better RFS rates in patients with tumors revealing a high
Ki67 LI (HR = 0.036, 95 % CI = 0.085 to 0.82, p = 0.021),
but not in patients with tumors showing a low Ki67. pCR
was predictive of better RFS in patients with tumors that
weakly expressed p27Kip1, (HR = 0.35, 95 % CI = 0.094
to 0.72, p = 0.010), but not in patients with tumors that
strongly expressed p27Kip1.
Discussion
In the present study, we clarified that NAC with taxanes
followed by FEC concurrently with trastuzumab was
useful for obtaining a high pCR rate of more than 65 %
and the statuses of high HG, low ER, low PgR, high
Ki67, and low p27Kip1 appeared to be predictive factors
for a high pCR rate. Furthermore, prognoses were sig-
nificantly better in patients with pCR and pathologically
negative lymph nodes after NAC with trastuzumab.
Trastuzumab, a humanized monoclonal antibody to
the HER2 protein, binds to the extracellular domain of
HER2, which is localized in the cell membrane of carcin-
oma cells, and inhibits their proliferation by arresting
the cell cycle during the G1 phase [9, 10]. Trastuzumab
has been suggested to inhibit HER2 action by preventing
HER2 dimerization and subsequent signal transduction
via the phosphatidylinositol 3-kinase (PI3K) cascade
[11, 12]. It also causes antibody-dependent, cell-mediated
cytotoxicity, and its binding to cancer cells triggers their
killing by immune cells [13, 14]. Since trastuzumab was
accepted as a new agent for breast cancer patients with
HER2 over-expressing tumors by the Food and Drug Ad-
ministration (FDA) in 1998, the strategy of breast cancer
treatment has markedly changed in the last decade.
Preclinical models suggested that the concurrent ad-
ministration of trastuzumab and chemotherapy was syn-
ergistic [15–17], and Siedman et al. [18] reported that
chemotherapy using trastuzumab (2 mg/kg) and paclitaxel
90 mg/m2 was clinically effective for metastatic breast
cancer patients with HER2-positive tumors, with overall
response rates ranging between 67 and 81 %. Trastuzumab
has also been used in adjuvant therapy, and Smith et al.
[19] reported that a 1-year treatment with trastuzumab
after adjuvant chemotherapy in the HERA study led to
significant overall survival benefits. When administered
concurrently with NAC, trastuzumab was shown to mark-
edly improve pCR rates in patients with HER2-positive tu-
mors [4, 7]. Buzdar et al. [8, 20] also reported a pCR rate
of 66.7 % in NAC with tri-weekly paclitaxel followed by
FEC concurrently with trastuzumab. Our modified regi-
men, such as “weekly paclitaxel instead of tri-weekly or
tri-weekly docetaxel”, also achieved a pCR rate of 65.1 %.
However, the pCR rate decreased to 61.2 % when the 5
patients with pathologically involved nodes were ex-
cluded. In addition, the foci of DCIS remained in
24.0 % of cases. Therefore, DCIS may be less responsive
to this kind of therapy because the carcinoma cells of
DCIS are localized in pre-existing lactiferous ducts
without feeding vessels.
Table 2 pCR prediction scores and their relationship with pCR
Scores pCR Non-pCR pCR rate (%) p-value
0 0 4 -
1 2 5 28.6
2 8 9 47.1
3 11 12 47.8
4 20 7 74.1
5 43 8 84.3 0.0001*
One point each was assigned for high HG, ER negative, PgR negative, high
Ki-67 LI, and low p27Kip1 expression
pCR, pathological complete response
*p < 0.05 was considered significant; significant values are shown in bold
Fig. 2 Relapse-free survival curve of pCR and non-pCR patient groups.
RFS was significantly better in patients with pCR after neoadjuvant
therapy than in those without pCR (HR = 0.40, p = 0.012)
Fig. 3 Overall survival curve of pCR patients with and without
lymph node metastasis. In pCR cases, OS was significantly better in
patients without lymph node metastasis than in those with lymph
node metastasis (HR = 13.34, p = 0.0002)
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Few studies have attempted to identify the predictive
markers of pCR after NAC in patients with HER2-
positive tumors [21, 22]. In our translational research to
obtain higher pCR rates, we clarified the relationship be-
tween pCR rates and the statuses of several biological
factors. The negative expression of hormone receptors
(ER and PgR) may be important for predicting pCR in
NAC with trastuzumab. The pCR rate of the ER-negative
group (78.6 %) was higher than that of the ER-positive
group (40.0 %), and was also higher in the PgR-negative
group (75.3 %) than in the PgR-positive group (38.9 %).
Furthermore, an evaluation of the high proliferation
marker (Ki67) LI was considered to be useful for estimat-
ing pCR, with the pCR of the high Ki67 (≥30 %) group
(72.0 %) being higher than that of the low Ki67 group
(47.2 %). An estimation of HG may also be useful for the
selection of high pCR patients because the pCR rate of the
high HG (grade 3) group was 70.0 % while that of the low
HG group (grade 1–2) was 36.8 %.
On the other hand, p27Kip1 is a cyclin dependent kin-
ase inhibitor that normally acts as a tumor suppressor
protein [23–26]; however, the relationship between the
expression of p27Kip1 and pCR in NAC with trastuzumab
has not yet been ascertained. Previous studies suggested
that breast cancers over-expressing HER2 become resist-
ant to trastuzumab by activating the PI3K/Akt signaling
pathway and downregulating p27Kip1 [27, 28]. Activated
Akt phosphorylates p27Kip1, which may result in the mis-
location of p27Kip1 to the cytoplasm, in which it is unable
to inhibit cell cycle proteins; nuclear localization is im-
portant for its cell cycle inhibitory function [29]. Low
amounts of p27Kip1 in the nucleus and resultant activation
of cyclin-dependent kinases in the nucleus may increase
the proliferation of tumor cells [30, 31]. Difficulties are as-
sociated with evaluating the expression of p27Kip1 because
3 potential expression patterns exist: only in the nucleus,
only in the cytoplasm, and in both the nucleus and
cytoplasm [32, 33]. Stendahl et al. [34] previously defined
grade 3 of p27Kip1 as 75 % or more cancer cells with
p27Kip1-positive nuclei. By using the same cut-off (75 %)
in the present study, we found that the weak expression of
p27Kip1 was predictive of pCR (low, 71.0 % vs. high,
50.0 %).
The results of the present study indicated that a set of
5 factors (HG, ER, PgR, Ki67, and p27Kip1) more accur-
ately predicted pCR than each factor individually. pCR
prediction scores of 0 to 5, which were calculated based
on the presence of a combination of these factors, pre-
dicted pCR rates of 0 % to 84.3 %. Prospective studies
are needed to determine whether pCR prediction scores
accurately predict pCR.
As reported in recent clinical trials on HER2-positive
breast tumors [6, 35], pCR after NAC with HER2-
targeted agents may be a surrogate marker of prognosis;
however, our results indicated that RFS was significantly
better in patients with pCR after NAC with trastuzumab
than in those with non-pCR. This result was consistent
with previous findings reported by the NSABP B-18 [2]
and B-27 [3] studies. In the NSABP B-27 trial, patients
without nodal involvement had significantly better OS
rates than those with nodal involvement if nodal involve-
ment was the only parameter analyzed, and OS rates de-
creased as the number of involved nodes increased [2].
As noted above, recent studies suggest that pCR criteria
include the lack of nodal involvement (e.g., “ypT0 ypN0”
and “ypTis ypN0”) [36]. In the present study, nodal in-
volvement was significantly predictive of low OS rates in
patients with pCR. Three out of the 5 patients with pCR
and nodal involvement had recurrent tumors; 2 were HER2-
negative residual tumors in the axillary nodes. Differences in
the expression of HER2 between primary breast tumors and
metastatic tumors in regional nodes or at distant sites may
reflect the heterogeneous characteristics of tumors.
HER2-positive tumors are ER-positive (designated luminal
B-like, HER2-overexpressing) or ER-negative (designated
non-luminal, HER2-enriched) [37]. In our study, pCR rates
were significantly higher in patients with non-luminal-like
tumors than in those with luminal-like tumors. Cross-talk
between the ER and HER2 signaling pathways in luminal-
like tumors may be responsible for the lower response of
these tumors to NAC with trastuzumab [38]. pCR was pre-
viously reported to be predictive of high survival rates in
most patients with breast cancer, but not in patients with
luminal-like tumors [22, 39]. However, as demonstrated in
the present study, pCR was predictive of RFS rates, even in
patients with luminal-like breast cancer if their tumors had
a high Ki67 LI (≥30 %). Therefore, pCR in combination with
a high Ki67 LI at baseline may be predictive of survival rates
in patients with luminal-like, HER2-overexpressing breast
cancer.
Conclusions
In the present study, we confirmed that NAC using tax-
anes followed by FEC concurrent with trastuzumab was
a useful regimen for obtaining a high pCR rate of more
than 65 %. By histopathological and immunohistochemical
evaluations, we identified high HG, ER-negative, PgR-
negative, high Ki67 LI, and low p27Kip1 as significant
predictive factors of pCR. In addition, significantly better
prognoses were achieved in the pCR group and patho-
logically negative lymph node group after this regimen of
NAC with trastuzumab.
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